Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 11/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 9/20 | 0.47 |
| ▸ | KDM5A | P29375 | 9/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDM5C | P41229 | 3/20 | 0.45 |
| ▸ | KDM6B | O15054 | 2/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.45 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TET3 | O43151 | 1/20 | 0.44 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473745 | 0.81 | KDM5B (0.50) | KDM4CKDM5BKDM5AKDM2BMAPT | |
| SCHEMBL5335080 | 0.81 | KDM4C (0.46) | KDM4CKDM5BKDM5AKDM2BTSHR | |
| SCHEMBL8283845 | 0.79 | ALDH1A1 (0.62) | TSHRKMT2ASMN1; SMN2KDM4EPOLB | |
| SCHEMBL6393382 | 0.78 | SMN1; SMN2 (0.62) | TSHRKMT2AMAPTSMN1; SMN2POLB | |
| SCHEMBL11565320 | 0.78 | HCAR3 (0.64) | TSHRKMT2AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL11340185 | 0.77 | KDM4E (0.55) | KDM4CKDM5BKDM5AMAPTKDM4A | |
| SCHEMBL6398480 | 0.77 | KDM4C (0.49) | KDM4CKDM5BKDM5AKMT2AMAPT | |
| SCHEMBL4851904 | 0.77 | NR3C2 (0.47) | MAPTSMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL15973575 | 0.76 | KDM4E (0.53) | KDM4CKDM5BKDM5AMAPTKDM4A | |
| SCHEMBL10266232 | 0.76 | KDM4C (0.55) | KDM4CKDM5BKDM5ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100424082-C | 4- (piperidinyl-pyrrolidinyl-alkyl-ureido) -quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1499607-B1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-07 | — | — | EP | disclosed |
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| CN-1617869-A | 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-05-18 | — | — | CN | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
| EP-1499607-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| EP-1379523-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003048154-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002076979-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-4276297-A | ANTIULCER AGENTS | PFIZER INC. (US) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | KDM4C 1980/4885KDM5B 2301/4885KDM5A 2723/4885 |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | KDM4C 2237/4885KDM5B 2040/4885KDM5A 2795/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | KDM4C 4172/4885KDM5B 3553/4885KDM5A 4201/4885 |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | KDM4C 965/4885KDM5B 1598/4885KDM5A 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.